We are live on ! Find out more

Abbott

ABT

Market cap $195B

112.47 USD

+0.88

0.79%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

112.48

+0.01

0.01%

1 day

0.79%

5 days

-3.28%

1 month

4.85%

3 months

30.32%

6 months

-1.45%

Year to date

-9.44%

1 year

-14.39%

5 years

-10.7%

10 years

160.05%

About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

Employees: 115,000

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 58.8%

Neutral 28.6%

Negative 12.6%

Zacks Investment Research

Why Abbott (ABT) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Abbott (ABT) is a Top Momentum Stock for the Long-Term

Best Dividend Aristocrats For September 2026

Dividend Aristocrats, tracked via NOBL, delivered a 12.9% YTD return, closely trailing SPY's 13.68%, with 29 Aristocrats outperforming SPY in 2026. Top 2026 performers include TGT (+73.04%), NUE (+55.64%), and BEN (+49.25%), highlighting strong sectoral momentum among select Aristocrats. Six Aristocrats announced dividend increases in the past month, pushing the group's average 2026 dividend growth rate to 4.30%, up from 4.10% last month.

Best Dividend Aristocrats For September 2026

Zacks Investment Research

Abbott (ABT) Stock Sinks As Market Gains: Here's Why

Abbott (ABT) concluded the recent trading session at $111.59, signifying a -2.2% move from its prior day's close.

Abbott (ABT) Stock Sinks As Market Gains: Here's Why

24/7 Wall Street

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?

Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication Amulet 360 builds upon Abbott's first-generation LAA device with design updates to enhance how the implant conforms to and seals the LAA to help reduce the risk of a stroke Recent clinical trial data show Amulet 360 met benchmarks for safety and effectiveness ABBOTT PARK, Ill., Aug. 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today it has received CE Mark for the Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce risk of stroke in patients with atrial fibrillation (AFib) not caused by a heart valve issue (non-valvular).

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients

The U.S. Food and Drug Administration said on Tuesday it authorized Abbott Laboratories' glucose monitor, making it the first device that continuously monitors both ketone ‌levels and blood sugar.

FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients

Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes

Libre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for people living with diabetes Designed to seamlessly address a critical gap in ketone monitoring, providing needed health data without adding burden on people living with diabetes Integrates with the latest-generation Libre app available in the U.S. and the full Libre digital health ecosystem; designed for compatibility with leading automated insulin delivery (AID) systems ABBOTT PARK, Ill., Aug. 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day system, the world's first dual glucose‑ketone sensing technology.

Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes

Zacks Investment Research

Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?

ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.

Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?

Zacks Investment Research

NVST or ABT: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and Abbott (ABT). But which of these two stocks presents investors with the better value opportunity right now?

NVST or ABT: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Here's What Is Shaping Abbott's Diagnostics Growth

ABT's Diagnostics growth is being reshaped as weaker respiratory testing offsets healthy routine demand and 13% cancer diagnostics growth.

Here's What Is Shaping Abbott's Diagnostics Growth

See News Rankings

Price charts implemented using Lightweight Charts™